<DOC>
	<DOCNO>NCT01149343</DOCNO>
	<brief_summary>The purpose clinical study examine safety , immunogenicity clinical activity immunotherapeutic product GSK2302025A ( also refer recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic [ ASCI ] ) administer first line treatment patient unresectable progressive metastatic cutaneous melanoma .</brief_summary>
	<brief_title>Evaluation New Vaccine Treatment Patients With Metastatic Skin Cancer</brief_title>
	<detailed_description>In study , patient receive maximum 24 dos recMAGE-A3 + AS15 accord four cycle period four year . An active follow-phase ( five year registration study ) plan patient . This protocol summary impact protocol amendment 3 , longer active follow-up patient discontinuation completion study treatment . The study end approximately 30 day last dose administer . In addition , biological sample collect protocol research purpose . For biological sample already collect scope study test yet , test perform default , except scientific rationale remain relevant . Sampling safety monitoring per protocol continue .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Male female patient histologically proven cutaneous melanoma . Phase I segment : All melanoma patient stage IV M1b stage IV M1c include completely resect stage IV patient exception stage IV M1c disease serum lactate dehydrogenase &gt; 1.5 x Upper Limit Normal involvement Central Nervous System . Phase II segment : All melanoma patient measurable , unresectable stage III melanoma include intransit metastasis ( ( N3 ) without ( N2c ) nodal metastasis ) stage IV M1a melanoma . The patient document progressive disease within 12 week registration trial . Patients resect stage IV stage IV M1b M1c disease include . 2 . Written inform consent PRAME expression screen gene profile resect tumor tissue complete study obtain patient prior shipment sample expression test prior performance protocolspecific procedure . 3 . The patient &gt; = 18 year old time sign first inform consent form . 4 . The patient 's tumor show expression PRAME antigen determine RTPCR analysis update technique fresh tissue sample . 5 . Eastern Cooperative Oncology Group performance status 0 1 . 6 . The patient adequate bone marrow reserve , renal , adrenal hepatic function assess standard laboratory criterion . 7 . Female patient nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . 8 . Female patient childbearing potential may enrol study , patient : practiced adequate contraception 30 day prior study product administration , negative pregnancy test day administration , agree continue adequate contraception entire treatment period 2 month completion study product administration series . 9 . In view investigator , patient comply requirement protocol . 1 . The patient time receive systemic chemotherapy , ( bio ) chemotherapy CTLA4 monoclonal antibody metastatic disease . 2 . The patient schedule receive anticancer treatment , include limited ( bio ) chemotherapeutic immunomodulating agent radiotherapy . 3 . The patient receive cancer immunotherapy contain PRAME antigen cancer immunotherapy his/her metastatic disease . 4 . The patient require concomitant treatment ( 7 consecutive day ) systemic corticosteroid immunosuppressive agent . 5 . Use investigational nonregistered product ( drug vaccine ) study product within 30 day precede first ASCI dose injection plan use study period 6 . The patient ( ) previous concomitant malignancy site ( include carcinoma situ ) , except effectively treat nonmelanoma skin cancer carcinoma situ cervix effectively treat malignancy remission 5 year highly likely cure . 7 . The patient allergy component study investigational product history previous allergic reaction vaccination . 8 . The patient history confirm adrenal dysfunction . 9 . The patient autoimmune disease , limited , multiple sclerosis , lupus , inflammatory bowel disease . 10 . The patient know positive human immunodeficiency virus ( HIV ) . 11 . The patient uncontrolled bleed disorder . 12 . The patient family history congenital hereditary immunodeficiency . 13 . The patient psychiatric addictive disorder may compromise his/her ability give inform consent comply trial procedure . 14 . The patient concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk . 15 . For female patient : patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PRAME</keyword>
	<keyword>Cancer immunotherapeutic</keyword>
	<keyword>Malignant melanoma</keyword>
	<keyword>ASCI ( Antigen-Specific Cancer Immunotherapeutic )</keyword>
</DOC>